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Abstract
 
In this study we have shown that activation of arthritogenic splenocytes with antigen and ago-
nistic anti-CD40 gives raise to a B cell population that produce high levels of interleukin (IL)-10
and low levels of interferon (IFN)-
 
 
 
. Transfer of these B cells into DBA/1-TcR-
 
 
 
-Tg mice,
immunized with bovine collagen (CII) emulsified in complete Freund’s adjuvant inhibited T
helper type 1 differentiation, prevented arthritis development, and was also effective in amelio-
rating established disease. IL-10 is essential for the regulatory function of this subset of B cells,
as the B cells population isolated from IL-10 knockout mice failed to mediate this protective
function. Furthermore, B cells isolated from arthritogenic splenocytes treated in vitro with
anti–IL-10/anti–IL-10R were unable to protect recipient mice from developing arthritis. Our
results suggest a new role of a subset of B cells in controlling T cell differentiation and au-
toimmune disorders.
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Introduction
 
CD40 is a member of the TNF superfamily and is ex-
pressed mainly on B cells and dendritic cells (DCs)
 
*
 
 as well
as endothelial cells, macrophages, T cells, and fibroblasts (1,
2). CD40-CD154 interaction is crucial for the production
of soluble factors such as cytokines (e.g., IL-6, TNF-
 
 
 
,
IL-12, IL-10, IL-1), chemokines (e.g., macrophage in-
flammatory protein-1 
 
 
 
), and for the up-regulation of
other costimulatory molecules such as CD80, CD86, and
CD54 (1). The CD40 pathway plays an important role in B
cell activation, inducing proliferation and isotype switching
(3, 4) while the engagement of CD40 expressed on DCs
drives their terminal maturation and the production of IL-12
(5). Given the broad effects mediated by the engagement of
CD40 with CD154, it is hardly surprising that blocking this
interaction, using for example anti-CD154 mAb, strongly
impaired the activation of antigen-specific immune response,
leading to reduced T cell priming, defects in effector func-
tion, and under specific circumstances to tolerance (6, 7).
Chronic collagen-induced arthritis (CCIA) is a Th1 cell–
dependent chronic arthritis, which develops after immuni-
zation of DBA/1-TcR-
 
 
 
-Tg mice with type II collagen
(CII) in CFA (8). Previous experiments from our labora-
tory showed that agonistic anti-CD40 surprisingly amelio-
rated established arthritis. After anti-CD40 treatment an in-
crease of IL-10 production and a decrease of IFN-
 
 
 
 release
was observed (9). These results suggested that the therapeu-
tic effect observed after administration of anti-CD40, could
have been achieved by redirecting pathogenic Th1 type re-
sponse toward the “protective” Th2 type (9).
In this study, we set out to investigate the basis of this
effect in detail. Although anti-CD40 treatment might work
by altering DCs or B cell function, two observations led us
to focus on the effect that anti-CD40 stimulation has on B
cells. First, CD40 activation of DCs, especially after stimu-
lation by bacterial components leads to IL-12 production
(5); this effect is unlikely to alleviate a Th1-driven disease.
Second, a number of studies have highlighted the influence
that B cells have on T cell differentiation (10–12) and on
the down-regulation of the IL-12 produced by DCs after B
cell CD40 engagement (11, 13). One of these studies has
also indicated that the influence of B cells on T cell differ-
entiation was mediated by cytokines, such as IL-6 and IL-10,
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Immunomodulation by B Cells
 
after CD40 activation (11). More recently, Harris et al.
have defined subset of B effector cells secreting cytokines
in a similar way to Th1 and Th2 cells (12). The same au-
thors have also shown that the cytokines produced by B
effector cells (Be1 and Be2), contribute to the in vitro dif-
ferentiation of naive T cell into Th1 or Th2 type (12).
Here we report that in vitro stimulation with an agonistic
anti-CD40 mAb and antigen generates B cells capable of
inhibiting Th1 differentiation and preventing as well as
ameliorating arthritis induced by CII/CFA immunization,
when injected into DBA/1-TcR-
 
 
 
-Tg mice. CII/anti-
CD40–stimulated B cells isolated from IL-10 KO mice
were unable to protect recipient mice from arthritis, sug-
gesting that IL-10 plays a key role in this mechanism of
immune suppression.
 
Materials and Methods
 
Mice.
 
The previously described heterozygous TCR-
 
 
 
 Tg
SWR/J mice were extensively backcrossed with DBA/1 mice in
order to derive the CCIA model (8, 13). Mice from generation
N15 typed for TCR-
 
 
 
 Tg expression, were selected for the ex-
periments. IL-10 KO in H2
 
q
 
 background were generated by
backcrossing the original IL-10 KO/H2
 
b
 
 (14) with DBA/1 H2
 
q
 
mice. The mice were typed by PCR and IL-10 KO
 
 
 
/
 
 
 
H2
 
q
 
 were
further backcrossed into DBA/1. Mice from the fourth genera-
tion (IL-10 KO
 
 
 
/
 
 
 
/H2
 
q
 
) were used for the transfer experiments.
 
Antibodies.
 
The treatment antibodies used were FGK45, rat
IgG, agonistic mAb reactive with mouse CD40; 1B1.2, rat IgG,
blocking mAb reactive with mouse IL-10 receptor (IL-10R)
(provided by F. Powrie, Oxford, UK); JES5–2A5, (rat IgG1) an
anti–mouse IL-10 mAb; 11.B.11 (rat IgG) neutralizing IL-4;
AFRC-Mac-1 (isotype control) rat IgG anti–dog chlamydomonas
cell wall glycoprotein (European Collection of Animal Cell cul-
ture, Salisbury, UK). The mAbs were purified from culture su-
pernatants by affinity chromatography, using a staphylococcal
protein G column (Bioprocessing) and filter sterilized. All anti-
bodies used throughout the experiments were below the limit of
detection for LPS levels using the Limulus Amebocyte lysate test
(Bio Whittaker Inc.).
The following mouse antibodies were purchased from BD
Biosciences. The mAbs used for FACS
 
®
 
 analysis were against
mouse CD3 PE or FITC, mouse CD19 FITC, mouse v
 
 
 
12 TcR
FITC (screening). The mAbs used for the intracellular detection
of cytokines were against mouse IFN-
 
 
 
 PE, IL-10 PE, and CD19
FITC or CD3 FITC mAbs. The coating/detection antibody pair-
ings used for ELISA are as follows; IL-4: ID11/24G2 (American
Type Culture Collection and BD Biosciences, respectively); IL-
10, rat mAbs 2A5/SXC-1: and IFN-
 
 
 
 (R46A2/XMG1.2),
American Type Culture Collection, courtesy of Dr. J. Abrams at
DNAX (Palo Alto, CA).
 
Preparation of Collagen.
 
Bovine CII was purified and prepared
as described previously (8). Bovine CII was solubilized by stirring
overnight at 4
 
 
 
C in 0.1 M acetic acid, to be used for immuniza-
tion, or 0.05 mM Tris-HCL, 0.2 M NaCl, pH 7.4, for in vitro
stimulation of splenocyte cultures.
 
Induction, Assessment of Arthritis and Histological Examination.
 
Sex-matched DBA/1-TcR-
 
 
 
-Tg mice (8–12-wk-old) were im-
munized with 100 
 
 
 
g of bovine CII emulsified in CFA (Difco
Laboratories). The development of arthritis was assessed daily for
the duration of the experiment. The clinical severity of arthritis
 
was graded as follows, 0 
 
 
 
 normal, 1 
 
 
 
 slight swelling and/or
erythema, 2 
 
 
 
 pronounced edematous swelling, 3 
 
 
 
 pronounced
edematous swelling plus light joint rigidity, 4 
 
 
 
 laxity (8). Each
limb was graded, allowing a maximal clinical score of 16 for each
animal. Swelling of hind paws was recorded with a pair of cali-
pers. All clinical evaluations were performed in a blinded manner.
 
Magnetic Sorting of Cells.
 
For the purification of B cells, single
cell suspensions from spleens isolated from arthritic DBA/1-
TcR-
 
 
 
-Tg mice were cultured at concentration of 5 
 
 
 
 10
 
6
 
cells/ml in complete medium for 48 h with: medium/isotype
control (AFRC-Mac-1; 5 
 
 
 
g/ml); 50 
 
 
 
g/ml of CII /isotype
control; medium/anti-CD40 (FGK45; 5 
 
 
 
g/ml); CII/anti-
CD40. Cells were pooled from different wells and washed with
complete medium; 10
 
7
 
 cells were then resuspended in 90 
 
 
 
l of
PBS, 0.5% of FCS, and 5 mM of EDTA. The cell suspensions
were incubated for 15 min at 4
 
 
 
C with 10 
 
 
 
l of anti-CD43 mag-
netic beads for negative selection or CD19
 
 
 
 magnetic beads for
positive selection (Miltenyi Biotec) per 90 
 
 
 
l of cell suspension.
The cells were washed twice to remove unbound beads resus-
pended in 500 
 
 
 
l of buffer (PBS, 0.5% FCS, 5 mM EDTA) and
purified using a magnetic activated cell-sorting (MACS) system.
FACS
 
®
 
 staining for the B cell marker CD19 was used to control
cell purity. This procedure normally yielded B cell preparations
which were 
 
 
 
95% CD19. DCs were purified as previously de-
scribed (15). DCs were depleted by positive selection, using
CD11c microbeads (Miltenyi Biotec), from spleens isolated from
arthritic mice, prior CII (50 
 
 
 
g/ml)/isotype control (5 
 
 
 
g/ml)
or CII/anti-CD40 (5 
 
 
 
g/ml) stimulation. Briefly, spleens were
isolated from at least eight arthritic DBA/1-TcR-
 
 
 
-Tg mice and
placed in Collagenase D (7 mg/ml). Spleens were then injected
with 500 
 
 
 
l of Collagenase D for 60 min at 37
 
 
 
C. The digested
suspension was then passed through a steel mesh using a plunger.
10
 
8
 
 cells were collected in a 50 ml tube, washed with buffer
(PBS, 0.5% FCS, 5 mM EDTA), and resuspended in 400 
 
 
 
l
buffer. The cell suspensions were incubated for 15 min at 4
 
 
 
C
with 100 
 
 
 
l of MACS CD11c Micro-Beads (Miltenyi Biotec)
per 400 
 
 
 
l of cell suspension. The cells were washed twice to re-
move unbound beads and resuspended in 500 
 
 
 
l of buffer (PBS,
0.5% FCS, 5 mM EDTA) for magnetic separation. FACS
 
®
 
 anal-
ysis was used to monitor the levels of CD11c
 
 
 
CD11b
 
 
 
 cells in
the negative fraction and less than 0.01% of any of these cells was
detected in the negative fraction. CD3
 
 
 
 T cells were purified
from spleen cell suspension by a positive selection procedure us-
ing anti–Thy-1.2 labeled micro-beads and MACS. This proce-
dure normally yielded cells which were 
 
 
 
98% CD3
 
 
 
 T cells.
CD4
 
 
 
 T cells were purified by positive selection using anti-
CD4
 
 
 
 labeled micro-beads.
 
Flow Cytometric Analysis of Intracellular IFN-
 
 
 
 and IL-10 Synthe-
sis.
 
Intracellular cytokine analysis was performed as described
previously (9, 12). Briefly, splenocytes or purified cells were re-
suspended at 5 
 
 
 
 10
 
6
 
 cells/ml with medium or CII (50 
 
 
 
g/ml)
for 48 h unless stated otherwise. PMA (50 ng/ml; Sigma-
Aldrich), ionomycin (500 ng/ml; Sigma-Aldrich), and Brefeldin
A (10 
 
 
 
g/ml; Sigma-Aldrich) were added for an additional 6 h. To
detect the surface Ags, cells were washed with PBS/BSA/azide
and then incubated with mouse anti-CD19 FITC-conjugated
mAb. After fixing (4% paraformaldehyde) for 10 min at 4
 
 
 
C, cells
were washed and permeabilized with PBS containing 1% BSA
and 0.5% saponin (Sigma-Aldrich) for 10 min. Permeabilized
cells were incubated with anti–mouse IFN-
 
 
 
 PE-conjugated, or
anti–mouse IL-10 PE-conjugated mAbs (BD Biosciences). To
demonstrate the specificity of staining, fixed/permeabilized cells
were incubated with excess of unlabeled anti–IFN-
 
 
 
 or anti–IL-T
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10 (BD Biosciences) before incubation with FITC anti–IFN-
 
 
 
or PE anti–IL-10. The cells were acquired with the FACScan™
flow cytometer (Becton Dickinson) and analyzed by WinMdi
software.
 
Spleen Cell Culture, Cytokines Quantification, Carboxyl Fluorescein
Succinimidyl Ester Labeling, and Adoptive Transfer to DBA/1-TcR-
 
 
 
-Tg Mice.
 
Spleens were removed from arthritic DBA/1-TcR-
 
 
 
-Tg mice on the day of clinical onset of arthritis. Single cell sus-
pensions were prepared and depleted of red blood cells with red
cell lysis buffer (Sigma-Aldrich), washed, and cultured in RPM1
1640 containing 10% (vol/vol) heat-inactivated FCS, 100 U/ml
penicillin, 100 
 
 
 
g/ml streptomycin, 2 
 
 
 
 10
 
 
 
5
 
 M 2-mercaptoeth-
anol, and 20 mM 
 
l
 
-glutamine. Splenocytes were cultured in 24-
well plates (Nunc) at a density of 5 
 
 
 
 10
 
6
 
 cells/ml in medium
alone or with 50 
 
 
 
g/ml of CII and 5 
 
 
 
g/ml of isotype control
(AFRC-Mac-1) or with 50 
 
 
 
g/ml CII and 5 
 
 
 
g/ml of anti-
CD40 (FGK45) 48 h. Purified B cells, B cell–depleted fraction,
or DC-depleted fractions were transferred intraperitoneally or in-
travenously to DBA/1-TcR-
 
 
 
-Tg at the time of CII/CFA im-
munization. Only CD19
 
 
 
 purified B cells, whose purity was
 
 
 
98%, were used in the transfer experiment.
B cells were purified by negative selection. CD43
 
 
 
 fraction
(CD19
 
 
 
 B cells) was labeled with the carboxyl fluorescein suc-
cinimidyl ester (CFSE) by incubation with 2 
 
 
 
l of CFSE (5 
 
 
 
M;
Molecular Probes) for 8 min at 37
 
 
 
C in PBS, followed by
quenching of the unlabeled CFSE with excess FCS and extensive
washing. CFSE-labeled B cells were then remixed with the
CD43
 
 
 
 fraction. The reconstituted splenocytes were cultured in
24-well plates at a density of 5 
 
 
 
 10
 
6
 
 cells/ml in medium alone
or with CII/isotype control (AFRC-Mac-1) or with CII/anti-
CD40 (FGK45) for 48 h. 10
 
7
 
 CFSE-labeled B cells were trans-
ferred intraperitoneally to DBA/1-TcR-
 
 
 
-Tg at the time of CII/
CFA immunization. 3 d after the in vivo transfer, spleens were
 
collected and cultured with medium or CII for 48 h. CFSE-
labeled B cells were sorted on a FACSVantage™ (Becton Dick-
inson). 5 
 
 
 
 10
 
5
 
 CFSE-sorted B cell were culture for 6 h with PMA
(50 ng/ml) and ionomycin (500 ng/ml). Supernatants were ana-
lyzed for cytokine secretion by ELISA. All populations were 98%
pure on reanalysis. For cytokines quantification splenocytes or
LNCs were cultured for 24 to 72 h. ELISA measured cytokine
productions as described previously (16).
 
Statistical Analysis.
 
For the statistical analysis of the data, the
Mann-Whitney U test and the Fisher exact test were applied to
analyze clinical results. Unpaired 
 
t
 
 tests were applied on cyto-
kine quantification experiments. P 
 
  
 
0.05 was considered sig-
nificantly different.
 
Results
Adoptive Transfer of Anti-CD40–treated Splenocytes Prevent-
ed the Evolution of Arthritis. We have previously shown
that in vitro anti-CD40 mAb (hereafter anti-CD40) stimu-
lation of splenocytes from arthritic mice prevented the
transfer of arthritis into SCID mice (9). Here we have ex-
amined whether the transfer of anti-CD40–treated in vitro
splenocytes to DBA/1-TcR- -Tg mice, at the time of CII
in CFA immunization, could also inhibit disease progres-
sion. Spleens were isolated from DBA/1-TcR- -Tg ar-
thritic mice, and restimulated in vitro for 48 h with CII/
anti-CD40 or with CII/isotype control (referred to as con-
trol). 5   106 splenocytes were transferred at the time of
CII in CFA immunization, intraperitoneally to DBA/1-
TcR- -Tg mice. A group of mice was also left untreated.
The results reported in Fig. 1 a show that while 100% of
Figure 1. Transfer of anti-CD40–stimulated spleno-
cytes inhibits arthritis in DBA/1-TcR-  Tg mice.
Spleen cells isolated from mice with established arthritis
were cultured in vitro for 48 h with CII/isotype con-
trol or CII/anti-CD40. 5   106 cells were transferred
to DBA/1-TcR-  Tg mice on the day of CII/CFA
immunization. A group of mice was left untreated. (a)
Incidence of arthritis; groups of mice were compared
by statistical analysis using the Fisher exact test. (b) Ar-
thritis severity; data are expressed as mean   SE.
Groups of mice were compared by statistical analysis
using the nonparametric Mann-Whitney U test. Data
are representative of three experiments.T
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DBA/1-TcR- -Tg mice injected with control splenocytes
developed severe arthritis, transfer of splenocytes chal-
lenged in vitro with anti-CD40 remarkably suppressed dis-
ease evolution in 80% of the recipient mice (Fig. 1 a). The
remaining 20% developed a significantly milder arthritis
compared with the control or untreated group (P   0.001;
Fig. 1 b).
Anti-CD40–mediated Protection Is B Cell Dependent. We
next investigated whether the protective effect induced af-
ter anti-CD40 treatment was either B cell or DC depen-
dent. B cells or DCs were depleted by immune-magnetic
positive selection, before in vitro CII/anti-CD40 or CII/
isotype control stimulation. After 48 h of incubation, 5  
106 total or B cell–depleted splenocytes were transferred to
DBA/1-TcR- -Tg mice at the time of CII/CFA immuni-
zation. Consistent with the results shown above, 70% of re-
cipient mice treated with anti-CD40 total splenocytes in
Fig. 2 a, and 30% in Fig. 2 b remained disease free until the
end of the experiment, while the remaining mice (30% in
experiment a and 70% in b) showed very mild signs of in-
flammation. The picture changed when B cells were de-
pleted before anti-CD40 stimulation. In this case, 100% of
the recipient mice developed arthritis within 27 d from CII
immunization (Fig. 2 a). Interestingly, a significantly earlier
day of onset was also observed in mice transferred with
control treated B cell–depleted splenocytes, compared with
those treated with total splenocytes (P   0.05; Fig. 2 a).
Next we evaluated the impact of depletion of DCs, before
in vitro anti-CD40 stimulation. 100% of mice transferred
with 5   106 cells control DC-depleted splenocytes devel-
oped arthritis. However, the disease onset was delayed
compared with mice treated with total splenocytes (Fig. 2
b). In contrast, only 25% of mice treated with DC de-
pleted, before anti-CD40 stimulation, splenocytes devel-
oped arthritis while the remaining 75% remained disease
free until the end of the experiment (Fig. 2 b). These re-
sults suggest that B cells, but not DCs, are involved in the
antiinflammatory effect induced by anti-CD40 observed in
the in vivo transfer experiments.
B Cells from Anti-CD40 Challenged Splenocytes Produce
CII-specific IL-10. B cells, in a fashion similar to T cells,
can differentiate into polarized subsets of Be 1 or Be 2 that
are capable of secreting unique cytokines (12). Therefore,
we next investigate whether B cells activated with CII and
anti-CD40 released detectable levels of IFN-  and IL-10.
Arthritogenic splenocytes were cultured in vitro with or
without CII and also with isotype control or anti-CD40 for
48 h. B cells were enriched by negative selection and the
release of cytokines was detected by intracellular staining as
described in Materials and Methods. Upon in vitro control
antibody stimulation, 11.06% of B cells produced IFN- ,
while 7.54% produced IL-10. After stimulation with anti-
CD40, the number of IFN- –producing B cells was re-
duced to 2.63% while the numbers of IL-10  B cells were
increased to 22.15% (Fig. 3 a). We also measured the levels
of IL-4 production under the same conditions and we
Figure 2. Are B cells the key players in the antiin-
flammatory effect mediated by in vitro stimulation
with agonistic anti-CD40? B cells or DCs were de-
pleted by positive selection from splenocytes isolated
from arthritic DBA/1-TcR-  Tg mice. Undepleted or
depleted splenocytes were stimulated with CII/isotype
control, CII/anti-CD40. After 48 h incubation, 5  
106 nondepleted or depleted cells were transferred in-
traperitoneally, at the time of CII/CFA immunization,
to DBA/1-TcR-  Tg mice. (a and b) Incidence of ar-
thritis. Mice groups were compared by statistical analy-
sis using the Fisher exact test. Data are representative of
three experiments.T
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found no differences between the different groups (unpub-
lished data). IFN-  and IL-10 release by purified B cells,
after PMA and ionomycin stimulation, were measured by
ELISA. As shown in Fig. 3 b, B cells purified from control
splenocytes produce IFN-  and a lower amount of IL-10.
On the contrary, B cells isolated from anti-CD40–stimu-
lated splenocytes produce IL-10 and little IFN- . In the
absence of CII stimulation the levels of IFN-  become un-
detectable in all groups, while a small amount of IL-10 was
released in the B cells isolated from anti-CD40 stimulated
splenocytes ( 500 pg; unpublished data).
To further test if IL-10 production required antigen
stimulation, B cells were negatively purified from arthrito-
genic splenocytes isolated from mice immunized with
CII/CFA or with CFA alone. To ensure B cell receptor
cross-linking, plates were precoated with CII. Negatively
purified B cells were added to CII-coated or uncoated
plates and cultured for 72 h in the presence of anti-CD40
and anti- . The results reported in Fig. 3 c show that B
cells (from CII/CFA immunized mice) incubated with an-
tigen alone do not produce detectable levels of IL-10.
Stimulation with anti-CD40 and CII only marginally in-
creased the production of IL-10 while higher levels were
detected upon culture with anti-CD40 and anti- . B cells
isolated from spleens of mice immunized with CFA alone
were unable to respond to anti-CD40 and CII stimulation;
however, high levels of IL-10 were measured upon anti-
CD40 and anti-  stimulation. Therefore, we can conclude
that the production of IL-10 required BCR engagement as
well as CD40 signal.
B Cells Isolated from Anti-CD40–stimulated Splenocytes Pre-
vent the Induction of Arthritis. We next evaluated whether
B cells, isolated from anti-CD40–treated splenocytes, can
protect recipient mice from developing arthritis. Spleno-
cytes isolated from DBA/1-TcR- -Tg arthritic mice were
cultured for 48 h with medium/anti-CD40, CII/anti-
Figure 3. Generation of B cells with a regulatory phenotype is controlled by endogenous IL-10. Arthritogenic splenocytes were cultured with CII/
isotype control, or CII/anti-CD40 for 48 h. B cells were then purified by negative selection and cultured with PMA plus ionomycin in the presence of
Brefeldin A for an additional 6 h. (a) The intracellular levels of IFN-  and IL-10 were measured using PE-conjugated mAb against IFN-  or IL-10 and
the purity of B cells was controlled using anti-CD19 FITC mAb. (b) Supernatant was collected from purified B cells stimulated in vitro with PMA plus
ionomycin and the secreted cytokines were measured by ELISA. Data show mean   SE of triplicate wells, and are representative of four experiments.
Data were compared by statistical analysis using the unpaired t test. (c) B cells were purified from arthritogenic splenocytes isolated from mice immunized
with CII/CFA or with CFA alone. Negatively purified B cells were cultured with or without CII anti-CD40, anti-CD40   anti-  for 72 h. Data are
representative of three experiments that gave similar results.T
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494 Immunomodulation by B Cells
CD40, or medium/isotype control, and CII/isotype con-
trol. 5   105 B cells were purified and transferred intra-
peritoneally to syngeneic mice at the day of CII/CFA im-
munization. More than 99% of purified B cells were
CD19 , and less than 1% expressed T cell (CD3; Fig. 4, e
and f), or myeloid (Mac-1) specific markers (unpublished
data). Fig. 4 a shows that only 20% of mice treated with B
cells isolated from CII/anti-CD40–treated splenocytes, de-
veloped arthritis and the disease severity was significantly
milder compared with that observed in the untreated
group (P   0.001; Fig. 4 b). 100% of mice transferred with
B cells isolated from CII/isotype control-treated spleno-
cytes developed disease by day 50 after immunization;
however, this group of mice showed a delay in the onset of
Figure 4. Transfer of B cells isolated from anti-CD40 activated splenocytes prevents chronic arthritis development. (a–c) DBA/1-TcR- -Tg spleno-
cytes were stimulated in vitro for 48 h with isotype control/CII; isotype control alone or with anti-CD40/CII or anti-CD40 alone. B cells were enriched
by negative selection, using an anti-CD43 magnetic beads conjugated antibody, and 5   105 B cells were transferred intraperitoneally, at the time of CII/
CFA immunization, to syngeneic mice. Percentage of mice with arthritis. Mice groups were compared by statistical analysis using the Fisher exact test.
(b–d) Severity of disease. The data represent the mean of (n) mice   SE and they are representative of five experiments. Groups of mice were compared
by statistical analysis using the nonparametric Mann-Whitney U test. The purity of B cells, isolated from (e) control or (f) anti-CD40–treated splenocytes,
was checked before transfer, by staining the negative fraction with FITC-conjugated anti-CD19 and PE-conjugated anti-CD3 mAbs. (c and d)
DBA/1-TcR- -Tg splenocytes were stimulated in vitro for 48 h with isotype control or with anti-CD40 alone. B cells were enriched by negative selec-
tion, using an anti-CD43 magnetic beads conjugated antibody, and 5   105 B cells were transferred intraperitoneally, at the time of CII/CFA immuni-
zation, to syngeneic mice. Percentage of mice with arthritis. (g) B cells were enriched by negative selection, using an anti-CD43 magnetic beads conju-
gated antibody, from DBA/1-TcR- -Tg arthritogenic splenocytes. Purified B cells were stimulated in vitro for 48 h with isotype control/CII; or with
anti-CD40/CII. 5   106 B cells were transferred intraperitoneally, at the time of CII/CFA immunization, to syngeneic mice. A group of mice was left
untreated. Percentage of mice with arthritis. Data are representative of four experiments.T
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arthritis and a significantly milder disease compared with
the untreated mice (P   0.01 Fig. 4 b). This finding sug-
gests that B cells with “protective” phenotype might be
present during an antigen-mediated inflammatory response
and their activity can be amplified by CD40 stimulation.
The protective effect mediated by anti-CD40–stimulated
B cells was found to be antigen dependent as B cells puri-
fied from anti-CD40–stimulated splenocytes cultured
without CII, fail to confer protection to the recipient mice
(Fig. 4, c and d).
To explore whether other cells within the splenic pool
were necessary to induce their secreting IL-10 phenotype,
B cells were purified by negative selection from arthritoge-
nic splenocytes and cultured in vitro with CII and anti-
CD40 or CII and isotype control for 48 h. Under this ex-
perimental condition 100% of the recipient mice treated
either with B cells from CII/isotype control or CII/anti-
CD40 treated splenocytes, developed severe arthritis (Fig. 4
g). No protection from arthritis was observed in mice
transferred with B cells cultured in medium alone and anti-
CD40 or with isotype control (unpublished data).
Transfer of CII/anti-CD40 Stimulated B Cells into Immu-
nized Mice Inhibits IFN-  Response and Up-regulates IL-10
Production. To test how the B cell transfer was influencing
the cytokines profile to auto-antigen in the host mice, we
assessed the recall responses to CII of LNCs and spleno-
cytes taken from B cell–treated mice.
Fig. 5 a shows that LNCs isolated from mice treated with
control or anti-CD40 stimulated B cells responded in vitro
to CII restimulation with a similar magnitude to those of
untreated mice. This observation suggests that transfer of
B cells into immunized mice does not appear to affect CII-
induced T cell activation assessed by proliferation.
Spleens were isolated from the same group of mice and
the levels of IFN-  and IL-10 produced by B cells were
detected by intracellular staining after CII in vitro restimu-
lation. Cytokine profiles revealed an inhibition in the num-
ber of IFN-    cells and an up-regulation of the expression
of IL-10–producing B cells in the CII/anti-CD40–stimu-
lated B cell–treated mice compared with CII/isotype con-
trol B cells and untreated (Fig. 5 b). The number of
IFN-   cells was undetectable in the absence of CII in the
control B cells group, while 5% of B cells produce IL-10 in
medium alone in the anti-CD40 B cells group (unpub-
lished data). Mice treated with control B cells showed a re-
duced number of IFN- –producing cells and a modest in-
crease of IL-10  B cells compared with the untreated
group (Fig. 5 b). To confirm that B cells transfer was influ-
encing Th1 differentiation, we assessed the recall response
to CII of T cells purified from LNCs isolated from control
and anti-CD40 B cell–treated mice. Consistently with the
results reported in Fig. 4 B, CD3  cells expressing IFN- 
(49.27%) were very high in arthritic control mice. In con-
trast, Th1 differentiation was completely suppressed in
mice treated with anti-CD40–stimulated B cells (Fig. 5 c).
Similar percentages of IL-10  CD3  expressing cells were
observed in the control or in the anti-CD40–stimulated B
cells group (Fig. 5 c).
Transferred B Cells Produce IL-10 Ex Vivo. We next in-
vestigate whether the B cells adoptively transferred into
syngeneic mice were able to produce IL-10 in vivo. Ten
million CFSE-labeled B cells were transferred to recipient
mice. 3 d later, CFSE  B cells were purified by sterile sort-
ing from spleens isolated from transferred mice, and IFN- 
and IL-10 levels were measured by ELISA after in vitro
stimulation as described in Materials and Methods. The re-
sults reported in Fig. 6 a show that higher levels of CII-spe-
cific IFN-  were detected in CFSE  B cells isolated from
animals transferred with CII/isotype control B cells com-
pared with anti-CD40-stimulated B cells group (P  
0.0002). In contrast, the latter B cells produce significantly
higher levels of IL-10 compared with CII/isotype control
B cells (P   0.001; Fig. 6 b). These results therefore suggest
that CII/anti-CD40 stimulated B cells are able to produce
IL-10 in vivo.
IL–10 Is Essential for the In Vivo Protective Effect of CII/
anti-CD40–stimulated B Cells. To determine whether the
IL-10 produced by CII/anti-CD40 stimulated B cells is di-
rectly involved in the suppression of arthritis, IL-10 KO
(H2b) mice were backcrossed into DBA/1 (H2q) mice and
the B cells from the IL-10 KO (IL-10KO/H2q) or wild-
type (IL-10 /H2q) mice were used for the transfer studies
after CII/anti-CD40 in vitro stimulation. Unlike B cells
isolated from the wild-type group, CII/anti-CD40–stimu-
lated B cells isolated from IL-10 KO mice were unable to
protect wild-type recipient from developing arthritis (Fig.
7, a and b). Additionally, in vivo neutralization of IL-10 ac-
tivity, by administration of neutralizing anti–IL-10 and
anti–IL-10r mAbs, also abolished the protective effect assert
by anti-CD40 B cell transfer (unpublished data), supporting
the hypothesis that B cells, throughout the provision IL-10,
interfere with the induction of arthritis.
IL-10 and CD4  T Cells Are Essential for the Generation of
B Cells which Can Suppress Arthritis. To establish whether
IL-10 is involved in the generation of the B cells able to
suppress arthritis, splenocytes were cultured with CII/anti-
CD40 or CII/isotype control in the presence of neutraliz-
ing anti–IL-10R mAb (17) or anti–IL-4 mAb. B cells were
purified by negative selection and 5   105 cells were trans-
ferred to immunized DBA/1-TcR- -Tg mice. Inhibition
of IL-10 during in vitro stimulation with CII/anti-CD40,
abrogates the protective effect mediated by anti-CD40–
stimulated B cells in recipient mice (Fig. 8 a). Thus, 100%
of the recipient mice treated with B cells isolated from
splenocytes costimulated with CII/anti-CD40 and anti-IL-
10R mAb developed arthritis within 36 d of immuniza-
tion. In contrast, neutralization of IL-4 did not affect the
protective effect of anti-CD40 (Fig. 8 a).
The lack of protection observed in mice treated with B
cells directly isolated from arthritogenic splenocytes fol-
lowed by CII/anti-CD40 in vitro stimulation (Fig. 4 g)
suggest that other “signals” in addition to anti-CD40 en-
gagement are required for the fully differentiation of B
cells with “protective” phenotype. CD4  T cells were de-
pleted, by positive selection, from arthritogenic spleno-
cytes before in vitro CII/anti-CD40 or CII/isotype con-T
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Figure 5. Treatment with anti-
CD40–stimulated B cells, inhibits
IFN-  production, and increases the
release of IL-10 in CII immunized
DBA/1-TcR- -Tg mice. Six DBA/
1-TcR- -Tg mice were injected in-
traperitoneally with B cells isolated
from isotype control or anti-CD40 in
vitro challenged splenocytes. A group
of six mice were left untreated. 20 d
after transfer draining lymph nodes
were isolated, and cultured in medium
alone or in the presence of CII for
72 h. (a) The proliferation of LNCs was
measured in medium alone or in re-
sponse to CII; data show mean   SE
of triplicate wells, and are representa-
tive of four experiments. Data were
compared by statistical analysis using
the Unpaired t test. (b) Splenocytes,
were cultured with CII/isotype con-
trol, or CII/anti-CD40 for 48 h PMA,
ionomycin and Brefeldin A were
added for an additional 6 h. The intra-
cellular levels of IFN-  and IL-10
were measured using PE-conjugated
mAb against IFN-  or IL-10. Spleno-
cytes were stained with FITC-conju-
gated mAb against CD19, to define
the percentage of B cells synthesizing
cytokines. Data are representative of
four experiments. (c) Lymph nodes
were isolated from the same group of
mice and cultured with CII/isotype
control, or CII/anti-CD40 for 48 h. T
cells were purified by positive selec-
tion using anti–Thy-1.2 magnetic
beads antibodies and cultured for an
additional 6 h with PMA, ionomycin,
and Brefeldin A. The intracellular lev-
els of IFN-  and IL-10 were measured
using and PE-conjugated mAb against
IFN-  or IL-10.T
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trol stimulation. After 48 h incubation, 5   106 CD4  T
cell–depleted splenocytes were transferred to recipient
mice. A group of mice was also treated with nondepleted
splenocytes challenged in vitro with CII/anti-CD40. Con-
sistently with the results reported in Fig. 2, 75% of mice
treated with nondepleted splenocytes treated with CII/
anti-CD40 remained disease free over 35 d after immuni-
zation. In contrast, 100% of mice treated with B cells dif-
ferentiated in the absence of CD4  T cells developed se-
vere arthritis (Fig. 8 b).
Therapeutic Effect of IL-10–producing B Cells on the De-
velopment of Established Arthritis. In the following experiments
we have tested the therapeutic potential of the anti-CD40
B cell transfer as a possible approach for the amelioration of
established arthritis. In the first experiment, CII/CFA
immunized mice were randomly assigned to a treatment
group and transferred with 5   105 B cells (intravenously),
isolated from splenocytes treated in vitro with either CII/
control antibody or CII/anti-CD40, on the first day of dis-
ease. The treatment was repeated on day 5 and 10 after dis-
Figure 6. In vivo cytokine production by anti-CD40 stimulated B cells
reisolated from spleen of treated mice. B cells were purified by negative
selection from arthritic splenocytes and labeled with CFSE. The labeled
fraction was reconstituted with the CD43 -positive fraction and cultured
with CII/isotype control or with CII/anti-CD40 for 48 h. 107 CFSE  B
cells were then transferred to immunized DBA/1-TcR- -Tg mice after
purification by negative selection. 3 d after the transfer, 5   106 spleno-
cytes were incubated in medium alone or with CII. 48 h later CFSE la-
beled B cells were sorted and stimulated for a 6 h with ionomycin and
PMA. The release of (a) IFN-  and (b) IL-10 was analyzed by ELISA.
The data (mean   SE of triplicate wells) are representative experiments,
using six to eight mice per group. Each experiment was repeated twice
with similar results. Data were compared by statistical analysis using the
unpaired t test.
Figure 7. B cells isolated from IL-10 KO/H2q mice
fail to differentiate into a “regulatory” phenotype.
Spleens were isolated from arthritic IL-10 KO/H2q
mice or from the control IL-10 wild-type mice. Sple-
nocytes were cultured for 48 h with CII/isotype con-
trol, CII/anti-CD40. B cells were enriched by negative
selection, using an anti-CD43 magnetic beads–conju-
gated antibody, and 5   105 cells were transferred in-
traperitoneally, at the time of CII/CFA immunization,
to IL-10 wild-type mice. Arthritis evolution and sever-
ity was measured as described previously. Data shows
incidence of arthritis (a) and mean of clinical score  
SE (b), and are representative of three experiments.
Groups of mice were compared by statistical analysis
using the Fisher exact test.T
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ease onset. A group of mice was also left untreated. Transfer
of anti-CD40 challenged B cell was found to be effective in
altering the course of disease when transferred after initiation
of arthritis (Fig. 9 a; P   0.002 versus antibody control or
untreated group). In contrast, transfer of B cell isolated from
splenocytes treated with antibody control produced no sus-
tained therapeutic effect on the progression of CCIA.
In the next experiment we aimed to assess whether anti-
CD40 B cells treatment is also efficient in mice with estab-
lished disease. DBA/1-TcR- -Tg mice immunized with
CII and CFA were treated at day 5 and 10 after disease on-
set. The results reported in Fig. 9 b show that the transfer
of anti-CD40 challenged B cells but not antibody control B
cells, significantly improved the severity of arthritis (P  
0.02 compared with untreated). However the efficacy of
the treatment was found to be less effective compared with
previous experiment where mice were treated during the
very early phase of arthritis.
Figure 8. (a) Generation of B cells with “protective”
phenotype is controlled by endogenous IL-10. Spleno-
cytes isolated from DBA/1-TcR- -Tg were cultured
with CII/isotype control, or CII/anti-CD40 for 48 h
alone or in the presence of neutralizing anti–IL-10R
mAb (1B1.2) or anti–IL-4 mAb (11B11). 5   105 B
cells were purified and transferred intraperitoneally to
DBA/1-TcR- -Tg mice at the time of CII/CFA im-
munization. Data are representative of two experi-
ments. Groups of mice were compared by statistical
analysis using the Fisher exact test. (b) Antigen-specific
CD4  T cells also play a crucial role in the generation
of B cells with “protective” phenotype. CD4  T cells
were depleted by positive selection from splenocytes
isolated from arthritic DBA/1-TcR-  Tg mice. Unde-
pleted or depleted splenocytes were stimulated with
CII/isotype control, CII/anti-CD40. After 48 h incu-
bation, 5   106 nondepleted or depleted cells were
transferred intraperitoneally, at the time of CII/CFA
immunization, to DBA/1-TcR-  Tg mice. Incidence
of arthritis. Mice groups were compared by statistical
analysis using the Fisher exact test. Data are representa-
tive of three experiments. 
Figure 9. Therapeutic effect of anti-CD40–treated B
cells on established arthritis. B cells were isolated from
CII/anti-CD40 or CII/isotype control stimulated arthrito-
genic splenocytes and enriched by negative selection.
DBA/1-TcR- -Tg mice were treated (intravenously) at
the day of disease onset and every 5 d (three doses in total)
with 5   105 B cells in the experiment (a) and at day 5 and
10 in experiment (b). The severity of arthritis is reported as
clinical score. Mice groups were compared by statistical
analysis using two-sided Student’s t test.T
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Discussion
We show here that B cells producing IL-10 arises after
stimulation of arthritogenic splenocytes with antigen (CII)
and agonistic anti-CD40 mAb. These IL-10–secreting B
cells when transferred to syngenic mice control the patho-
genic Th1 response (8), inhibit the onset of CCIA, and
treat ongoing disease.
How These B Cells Work In Vivo? The development of
CIA in DBA/1 mice involves the induction of CII specific
Th1 cells (16, 18), as supported by the beneficial effect ob-
served after neutralization of IFN-  or IL-12 during the
early phase of disease (19, 20). On the other hand IL-10 / 
mice showed an exacerbated disease compared with the
wild-type, suggesting that this cytokine is involved in the
down-regulation of the autoimmune response initiated by
CII in CFA immunization (21). In this context CIA is
ameliorated by administration of rIL-10 (22); however, the
effect is transitory, and disease flares after interruption of
the treatment. On the contrary, transfer of B cells produc-
ing IL-10 provides a long lasting effect. We have also gen-
erated preliminary results suggesting that the transfer of B
cells can ameliorate established arthritis and therefore this
approach might represent a very attractive strategy to treat
autoimmune diseases, as the IL-10 can be delivered by the
B cells in an antigen-specific fashion to the crucial site of
priming or inflammation.
The obvious explanation of this data is that the IL-10
made by these B cells inhibits the inflammatory cascade ini-
tiated by CII/CFA immunization. This could be achieved
throughout a constant supply of IL-10 by transferred B cells
that may induce the production of other antiinflammatory
soluble factors (i.e., TGF- ) or the differentiation of cells
with “regulatory” activity.
IL-10 plays an important immuno-regulatory role in the
homeostasis of the immune system. The antiinflammatory
activities of IL-10 include inhibition of antigen-specific T
cell proliferation and the down-regulation of costimulatory
molecules on the APCs, which are directly involved in the
differentiation of Th1 response (23, 24). In addition IL-10
directly suppresses the release of the inflammatory cyto-
kines produced by macrophages and monocytes (25). In
our model, the histological analysis of the protected paws
showed a lack of recruitment of inflammatory cells in the
synovium, suggesting that B cells, via the production of IL-
10, are involved in the down-regulation of the inflamma-
tory cascade initiated after CII/CFA immunization. We
have taken a further step in showing that the protection
was IL-10 dependent. Indeed, neutralization of IL-10 after
transfer inhibited the protective effect assert by B cells pro-
ducing IL-10 (unpublished data). Whether this is due to
the disruption of the inflammatory cascade induced by
pathogenic Th1 cells, or due to the lack of migration of the
pathogenic T cell itself in the joints is not known. A similar
scenario is well described in IBD models for colitis, where
regulatory CD4 CD25  T cells mediate their protective
effect by releasing IL-10 and TGF  (26). In this model, the
importance of IL-10 was confirmed by the finding that
CD4 CD25  T cells from IL-10 KO mice did not prevent
IBD, whereas CD4 CD25  T cells from IL-10  mice did
(17). Similarly, anti-CD40–stimulated B cells isolated from
IL-10 KO mice did not prevent arthritis development,
while anti-CD40–stimulated B cells isolated from IL-10
wild-type mice significantly reduced the severity of disease
in the recipient mice. Therefore, all our in vivo and in
vitro results point to B cells as the crucial role of IL-10 in
the down-regulation of the inflammatory cascade initiated
after immunization.
It has been previously shown that CD40 engagement is
one of the early events in a cascade of signals passing back
and forth between T cells and APCs and that can augment
activation or modulate the response, for instance by push-
ing Th2 differentiation or the generation of T regulatory
cells (27). In our model it could be argued that the pro-
duction of IL-10 by B cells might induce the differentia-
tion of Tr1 regulatory CD4+ T cells (28). However, this
seems unlikely in this system as T cells purified after in
vitro anti-CD40 stimulation failed to protect the recipient
mice from disease.
Recent in vitro studies have suggested a model in
which Th2 differentiation is controlled by cytokines re-
leased by a subset of B cells (11, 12). In this in vitro model
the ability of “B effector” 2 cells to promote Th2 differ-
entiation in vitro it appears to be due through the pro-
duction of IL-4. While we have not found IL-4 to be
made by B cells, in our system we do show that B cells
producing cytokines, in this case IL-10, strongly affect the
polarization of T helper cell differentiation, resulting in
the inhibition of antigen-specific Th1 response. These
data show that the dialogue between B and T cells during
an (auto)-immune response is not one sided and demon-
strate that B cells have a strong impact in conditioning T
cell differentiation.
A potential “protective” role of B cells in autoimmune
diseases was previously suggested by Wolf et al. using an
EAE model (29), showing more severe disease in B cell–
deficient mice. Recently work by Fillatreau et al. has ex-
tended this by investigating the development of EAE in
bone marrow chimeras mice in which B cells, but not T
cells or APCs, are deficient in IL-10 production. Such chi-
meric mice exhibit a more severe EAE disease course with-
out going into the remission phase that is normally seen in
wild-type mice (or control chimeras). This prolonged dis-
ease is correlated with high levels of IFN-  without any ac-
companying loss of the IL-4 response. Similarly, chimeras
in which only B cells are deficient in CD40, also exhibit
the more severe EAE, indicating that CD40 activation of B
cells precedes IL-10 production (30). These results are in
complete agreement with our findings, and strengthen the
conclusion that upon CD40 engagement B cells differenti-
ate into a B regulatory population and that their generation
is also IL-10 dependent.
The observation that a subset of B cell acquires a regula-
tory function after anti-CD40 stimulation reinforces theT
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concept that CD40 might have a role in a negative feed-
back loop that in this model would lead to the control of
Th1 differentiation by B cells. However, the fact that direct
stimulation of purified B cells with antigen and anti-CD40
failed to trigger the differentiation of B cells into a regula-
tory phenotype suggest that more complex cell/cell inter-
actions are required for their differentiation. In particular
the results shown in Fig. 8 b suggest that during the induc-
tion phase there is a cross-talk between B cells and CD4 
T cells. Previous data have shown that in vitro BCR en-
gagement and CD40 stimulation are required for the pro-
duction of IL-10 by B cells (11). However, in our system
these coupled signals alone do not appear to be sufficient
for the generation of B cell with a “protective” phenotype.
This could be due to limiting amounts of IL-10 released in
this experimental condition, compared with those pro-
duced by B cells isolated from arthritogenic splenocytes
cultured with CII/anti-CD40. We know that IL-10 is also
important for the generation of such B cells as addition of
anti–IL-10r/anti–IL-10 during in vitro stimulation abro-
gates their development. Therefore, we could envisage that
CD4  T cells either directly via the release of soluble fac-
tors (i.e., factors inducing IL-10 or IL-10 itself) or indi-
rectly by cell–cell contact is necessary for the development
of high level cytokine secreting B “effector” cell. Thus, our
data, together with those recently published describing a
role for IL-10–producing B cells in regulating Th2-driven
chronic intestinal inflammation, introduce a “regulatory”
function for B cells in T cell dependent chronic inflamma-
tory disorders (31).
In summary, our study shows that antigen-specific B
cells, activated in the presence of T cells and additionally
CD40 engagement, produce IL-10 and that these B cells
play an important immunoregulatory role in a model of
arthritis. More consideration to the cytokines specifically
released by B cells and to their effect on T cells differen-
tiation is needed to understand the mechanisms that reg-
ulate antigen-specific immune responses in chronic in-
flammatory disorders. These results also shed light on
how in vivo anti-CD40 treatment may ameliorate ar-
thritis by inducing the generation of B cells capable of
controlling the proinflammatory Th1 type response via
the release of IL-10. Our study, by showing how to in-
duce this subset of B cell in CCIA, will help in the study
of their role in health and disease and might provide the
basis for novel therapeutic approaches for rheumatoid
arthritis.
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